Saint Francis Hospital and Medical Center
The Mandell MS Center


Host to the Multiple Sclerosis Brain Symposium 2016 | About Joyce and Andy Mandell


Responsiveness to Dalfampridine Treatment Among Multiple Sclerosis Patients Followed at the Mandell Multiple Sclerosis Center Identifier: NCT01399957

Mount Sinai Rehabilitation Hospital
490 Blue Hills Ave
Hartford, CT 06112

Short Description

Ampyra (dalfampridine) has been approved by the FDA for improving walking speed in persons with multiple sclerosis (MS). This observational study was designed to capture information on additional possible benefits person’s taking Ampyra may or may not experience. This project seeks to determine factors that will predict a response (an increase in walking speed) to dalfampridine. A second goal is to identify possible additional benefits to taking Dalfampridine.


Status Closed to enrollment, in data analysis phase only.

Principal Investigators Albert Lo, MD, PhD and Elizabeth Triche, PhD

Contact Name Kayla Olson, Study Coordinator

Phone (860) 714-3005


The Mandell MS Center
490 Blue Hills Avenue
Hartford, CT 06112